Aptamers recognize their targets with extraordinary affinity and specificity. The aptamer-based therapeutic, Macugen, is derived from a modified 2fluoro pyrimidine RNA inhibitor to vascular endothelial growth factor (VEGF) and is now being used to treat the wet form of age-related macular degeneration. This VEGF 165 aptamer binds specifically to the VEGF165 isoform, a dimeric protein with a receptor-binding domain and a heparin-binding domain (HBD). To understand the molecular recognition between VEGF and this aptamer, binding experiments were used to show that the HBD contributes the majority of binding energy in the VEGF 165-aptamer complex. A tissue culture-based competition assay demonstrated that the HBD effectively competes with VEGF165 for aptamer binding in vivo. Comparison of NMR spectra revealed that structural features of the smaller HBD-aptamer complex are present in the full-length VEGF 164-aptamer complex. These data show that the HBD provides the binding site for the aptamer and is the primary determinant for the affinity and specificity in the VEGF 165-aptamer complex.
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age-related macular degeneration ͉ Macugen ͉ RNA ͉ NMR V ascular endothelial growth factor (VEGF) is an essential growth factor and is the key angiogenic factor for development, proliferation, and maintenance of a healthy vasculature. VEGF is also involved in pathologic angiogenesis, such as age-related macular degeneration (AMD), ischemic heart disease, tumor growth, and metastasis (1, 2) . One isoform, VEGF 165 , is the major inducer of abnormal blood vessel growth and leakage in the wet form of AMD, a vascular disease of the eye that leads to rapid vision loss and blindness in millions worldwide (1, 3, 4) . Inhibiting VEGF 165 in the eye is therefore a promising approach for controlling angiogenesis in AMD (5) .
VEGF 165 consists of two domains, a receptor-binding domain that is present in all four isoforms of VEGF and a heparinbinding domain (HBD) that distinguishes VEGF 165 from the other soluble isoforms (1) . The 3D structures of each domain have previously been determined (6, 7) . The receptor-binding domain interacts with cell-surface tyrosine kinase receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR, Flk-1), triggering the signaling cascade that leads to angiogenesis (1, 2) . Antibody fragments that target the receptor-binding domain and therefore inhibit receptor binding are currently used in cancer treatment and are also in clinical trials for wet AMD (1) . These antibodies inhibit all isoforms of VEGF. In contrast, a nucleic acid-based inhibitor, Macugen, currently used in treatment of wet AMD (5) is an isoform-specific inhibitor of VEGF 165 that does not recognize VEGF 121 , which lacks the HBD (8) .
Aptamers are nucleic acids that are generated by the SELEX (systematic evolution of ligands by exponential enrichment) in vitro evolution technology (9, 10) . The VEGF 165 aptamer, also called NX1838 or pegaptanib sodium, is a potent inhibitor of angiogenesis and was used to develop the drug Macugen (5, 11) . This aptamer is a modified RNA derived from a 2Јfluoro pyrimidine aptamer and also contains 2ЈO-methyl purine modifications to enhance stability against endonucleases (Fig. 1A) . For effective treatment of AMD in humans, the aptamer is further modified with a 5Ј polyethyleneglycol moiety and a 3Ј dT attached via a 3Ј-3Ј linkage to confer favorable pharmacokinetic properties and for protection against exonucleases (8) .
This aptamer binds to VEGF 165 with extremely high affinity (K d ϭ 50 pM), and animal studies and clinical data have demonstrated the efficacy of the aptamer in preventing blood vessel growth and arresting the progression of wet AMD (8, (11) (12) (13) (14) . However, the detailed molecular mechanism by which this aptamer achieves isoform-specific inhibition of VEGF 165 is not well understood. An efficient photo-crosslink has been obtained between the HBD and the aptamer, suggesting this aptamer recognizes VEGF 165 by targeting the HBD (8) . The focus of the studies here is to characterize the role of the HBD in isoform-specific recognition of VEGF 165 by the aptamer. NMR spectroscopy was used to compare the isolated HBDaptamer complex and the full-length VEGF 164 -aptamer complex. The results lead to valuable insights into the molecular mechanism of inhibition of this aptamer therapeutic.
Materials and Methods
Sample Preparation. Pegylated and nonpegylated aptamers ( Fig.  1 A) were obtained from Transgenomics (Omaha, NE) and exchanged into NMR buffer (10 mM Tris-d 11 , pH 7.0͞100 mM NaCl͞0.55 mM CaCl 2 ͞0.05 mM EDTA͞90% H 2 O͞10% D 2 O) by repeated concentration in Centricon YM-3 centrifugal filter devices (Millipore), resulting in a 1-mM NMR sample.
NMR quantities of 15 N-labeled HBD (VEGF 111-165 ) were produced from a Pichia pastoris expression system (Invitrogen). Multiple copies of the expression cassette were stably inserted into the genome of strain KH71, and a methanol-inducible AOX1 promoter controlled expression of secreted HBD. Cells were grown in minimal media with glycerol supplemented with histidine, according to the supplier's recommendations. The cells were transferred to methanol containing minimal media (30-40 OD 600 ͞ml) with 10 g͞liter 15 N ammonium sulfate, and protein induction was maintained for 32 h at 30°C. The media were collected, and the HBD was purified on a 5-ml heparin Sepharose column (HS Hitrap, Amersham Pharmacia) in 10 mM Tris, pH 7.5, with a salt gradient between 0.1 and 1.5 M NaCl. The peak containing the folded HBD was identified by NMR spectroscopy and exchanged into NMR buffer. Yields of Ϸ7 mg͞liter were obtained as determined with the BCA protein assay (Pierce).
The HBD-aptamer complex was formed either by adding 15 N-labeled HBD to the aptamer or adding the aptamer to the HBD. 1D imino proton spectra of the aptamer and 2D 1 H-15 N heteronuclear single quantum correlation (HSQC) spectra of the protein were used to monitor complex formation. The final sample concentration was 0.5 mM, and a small excess (Ͻ15%) of aptamer was added to samples used for resonance assignment of the HBD in the HBD-aptamer complex.
The mouse protein VEGF 164 was used for the NMR studies on full-length VEGF. This protein is identical to human VEGF 165 except that it is missing the C-terminal Arg residue. The aptamer binds with equal affinity to the full-length human (VEGF 165 ) and mouse proteins. NMR quantities of deuterated 15 N-labeled VEGF 164 were produced from the P. pastoris expression system (Invitrogen) as described above for the HBD, except that cells were first conditioned to 25% D 2 O in glycerol containing minimal media before transferring the cells to expression media in 80% D 2 O (with methanol and 10 g͞liter 15 N-labeled ammonium sulfate). VEGF 164 was purified as described above for the HBD and exchanged into NMR buffer. The VEGF 164 -aptamer complex was formed by adding VEGF 164 and aptamer at a 1:1 ratio to a final concentration of 0.1 mM in NMR buffer. 1D imino proton and 2D 1 H-15 N transverse relaxation optimized spectroscopy (TROSY)-HSQC spectra were used to monitor complex formation (15) .
EMSA. EMSAs were used to determine the affinity of the aptamer for the HBD. Increasing amounts of HBD were incubated with 500 pM 32 P-labeled aptamer in NMR buffer at 25°C for 30 min. Free and HBD-bound aptamers were resolved on a native 12% polyacrylamide gel at 4°C in 0. 5 were cultured in M200 media supplemented with 1ϫ low supplement growth serum (Cascade Biologics, Portland, OR) and antibiotics at 37°C. Four hours before the experiment, HUVEC were serum-starved in M200 media with 1% FBS and antibiotics. All treatments afterward were performed in these media. HUVEC were incubated with VEGF 165 (328 pM), VEGF 165 plus 1.5 nM pegylated aptamer, or VEGF 165 plus 1.5 nM pegylated aptamer and increasing concentrations of HBD (2.3-300 nM) for 1 h. HUVEC were also incubated with DTT-inactivated HBD, VEGF 121 , or media alone (untreated cells) as control experiments. Total RNA was isolated by RNeasy Mini RNA Isolation Kits (Qiagen, Valencia, CA). TF mRNA expression levels were measured by real-time RT-PCR (TaqMan) analysis using primers specific for human TF mRNA (Applied Biosystems). The TF mRNA levels were normalized to the untreated sample.
NMR Spectroscopy. NMR experiments were carried out on Varian Inova 500-, 600-, or 800-MHz spectrometers, equipped with triple resonance z axis pulsed-field gradient probes. The 600-MHz spectrometer used a cryogenic probe. The TROSY-HSQC experiments of the free VEGF 164 and VEFG 164 -aptamer complex were performed at 800 MHz. The 31 P 1D data were acquired with a broadband probe at 500 MHz. 1D data were processed with the program FELIX (Accelrys, San Diego). 2D and 3D data were processed with the program NMRPIPE (17) and analyzed by the program SPARKY (18) . External 2-2-dimethyl-2-silapentane-5-sulfonate was used for the 1 H and 15 N reference, and external sodium phosphate was used as the 31 P reference.
Resonance Assignments. The average chemical shift differences of the amide proton and nitrogen resonances between the free HBD and HBD in the complex were calculated by using Eq. 1 (19),
where ⌬␦ H and ⌬␦ N are the chemical shift differences of the amide proton and nitrogen resonances between free HBD and HBD in the complex.
Results
The VEGF Aptamer Forms a Specific Complex with the HBD of VEGF165.
EMSAs were used to probe the affinity for the aptamer to the HBD (Fig. 6 , which is published as supporting information on the PNAS web site (8) . 2D NOESY spectra were used to assign the imino proton resonances and confirm the secondary structure of the aptamer shown in Fig. 1 A. Fig. 2A shows the titration of aptamer with HBD, where the imino proton spectrum changes until a 1:1 complex is formed and no free aptamer is observed (the U10 resonance at 11.74 ppm is indicative of free aptamer). Further addition of HBD resulted in no change in the imino proton spectrum (data not shown). The formation of the 1:1 HBDaptamer complex was also monitored by 2D 1 H-15 N HSQC spectra. Both 1D imino proton and 2D HSQC spectra exhibited slow exchange of the NMR resonances, as expected for a tight binding complex.
The HBD Competes In Vivo with Full-Length VEGF165 for Aptamer
Binding. A VEGF-induced TF expression assay in HUVEC was used to demonstrate the direct binding of the aptamer to the HBD in vivo (16) . HUVEC up-regulate the expression of TF in response to VEGF 165 , and this up-regulation can be suppressed by the aptamer (Fig. 1B) . Upon addition of HBD, the suppression of TF expression by the aptamer is reversed, because the HBD competes with full-length VEGF 165 for aptamer binding. HBD reverses the inhibition of VEGF 165 by the aptamer with an EC 50 in the low nM range (Fig. 1B) . Competition of HBD and VEGF 165 for aptamer binding was observed only with native HBD, and no effect was observed upon addition of 300 nM DTT-inactivated HBD. The results on the unfolded HBD demonstrate that the competition between the HBD and VEGF 165 for aptamer binding is not simply caused by favorable electrostatic interactions between the positively charged HBD and the aptamer. Furthermore, VEGF 121 -induced TF expression in HUVEC was not affected by the addition of aptamer and͞or HBD, confirming the specificity of the aptamer for VEGF 165 . These results demonstrate that HBD can effectively compete with full-length VEGF 165 for aptamer binding in vivo.
Comparing the Aptamer Conformation in the HBD-Aptamer Complex
and the VEGF 164-Aptamer Complex. Fig. 2B shows the imino proton spectra of free aptamer, the aptamer bound to the HBD, and the aptamer bound to VEGF 164 . The imino proton spectra of the two complexes are very similar, demonstrating that the secondary structure of the aptamer is maintained between the HBD-and the VEGF 164 -aptamer complexes. The two additional resonances in the VEGF 164 -aptamer complex were tentatively assigned to the imino proton of U20 (11.61 ppm) in the internal loop of the aptamer and to the amide proton of C57 (11.96 ppm), based on previously published assignments of the receptorbinding domain of VEGF (20). 31 P chemical shifts are a sensitive probe of unusual backbone conformations of oligonucleotides and are especially valuable for studying protein-nucleic acid interactions (21, 22) . Fig. 2C compares the 31 P spectra of the free aptamer with the aptamer bound in either the HBD or the VEGF 164 complex. There is a striking change in the 31 P spectrum of the aptamer when bound to HBD, with resonances dispersed over 7 ppm. This 31 P fingerprint is therefore diagnostic of the HBD-aptamer interaction. Ignoring the differences in line widths resulting from the size difference between the two complexes (63 versus 15.6 kDa), the 31 P spectra of the two complexes are essentially the same. These data demonstrate that the backbone conformation of the aptamer and the interactions with the phosphates are conserved between the HBD-aptamer and the VEGF 164 -aptamer complexes. 15 N HSQC spectra at 10°C of free HBD (blue) and aptamer-bound HBD (red). Backbone resonance assignments are indicated in blue (free HBD), red (HBD-aptamer complex), and black (free and bound HBD). Boxes illustrate the NMR fingerprint created by residues S121, T142, and T157 in the HBD-aptamer complex.
HSQC, 1 H-15 N HSQC-total correlation spectroscopy). In the 1 H- 15 N HSQC spectrum of the HBD-aptamer complex, 48 of the 50 expected amide backbone crosspeaks were assigned, and the two N-terminal resonances were not observed (Fig. 3) . The secondary structure of the HBD in the complex with the aptamer was assessed from sequential and medium-range NH-NH and NH-H␣ NOE patterns in the 1 H-15 N NOESY-HSQC spectra (Fig. 7 , which is published as supporting information on the PNAS web site). The ␤1-␤2-␣-␤3-␤4 secondary structure of the free HBD (6) is basically unchanged in the complex, allowing the use of chemical shift mapping to probe the aptamer binding site.
The weighted average 1 H͞ 15 N backbone chemical shift changes were determined for each residue by using Eq. 1. These chemical shift changes are clustered in three regions in the amino acid sequence (Fig. 4A) . The residues S121, T142, and T157 represent the largest backbone chemical shift perturbations in each affected region. Comparison of the 1 H-15 N HSQC spectra of free HBD and aptamer-bound HBD (Fig. 3 ) reveals that these three residues form a well resolved 1 H͞ 15 N NMR fingerprint that is diagnostic of the HBD-aptamer complex. (15) . The presence of only one set of resonances for the protein and aptamer in these spectra confirm that the 2:2 VEGF 164 -aptamer complex forms a symmetric dimer in solution. Fig. 5 shows a superimposition of TROSY-HSQC spectra on the HBD-aptamer and VEGF 164 -aptamer complexes. The triad of residues S121, T142, and T157 displays the same crosspeak pattern in both the HBD-and VEGF 164 -aptamer complexes. The crosspeak for S121 is shifted away from other crosspeaks and has a similar position in both complexes. Fig. 5B shows that crosspeaks for residues T142 and T157 in the VEGF 164 -aptamer complex overlap exactly with those in the HBD-aptamer complex. Additional evidence for these assignments is the absence of crosspeaks at these positions in the spectrum of free VEGF 164 (boxes in Fig. 5C ), demonstrating that these crosspeaks do not arise from the receptor-binding domain. Further analysis showed that almost all of the 1 H͞ 15 N crosspeaks in HBD-aptamer complex overlap with crosspeaks in the full-length complex with only two exceptions, where changes for these two residues arise from the presence of the receptor binding domain (data not shown).
Discussion
The VEGF Aptamer Recognizes the HBD in the VEGF165-Aptamer Complex. The studies here are designed to probe the intermolecular interactions between the aptamer and the HBD in VEGF 165 . Previous studies have shown that the aptamer does not recognize the shorter VEGF 121 isoform, which lacks the Cterminal HBD of VEGF 165 (8) . In addition, the negatively charged aptamer is predicted to target the positively charged HBD (calculated pI of 11.6), and a unique photo-crosslink has been observed between C137 in the HBD of VEGF 165 and a 5-iodo U14-modified aptamer (8) . We have shown that most of the binding energy for the aptamer is provided by the HBD, with a ⌬⌬G°between the HBD-and VEGF 165 -aptamer complexes of Ϸ3 kcal͞mol or Ϸ23% of the binding energy. Furthermore, results from the in vivo VEGF-induced TF expression assay demonstrated that the aptamer suppresses VEGF 165 -induced TF expression with an EC 50 that is equivalent to the K d measured in vitro (Figs. 1B and 6 ).
The Local Structure of the HBD-Aptamer Complex is Conserved in the
Full-Length VEGF164-Aptamer Complex. NMR spectroscopy was used to probe the conformations of both the aptamer and the HBD in the HBD-aptamer and the VEGF 165 -aptamer complexes. Imino proton spectra provide information on nucleic acid secondary structure, and the spectra in Fig. 2B show there is no significant change in secondary structure of the aptamer in these two complexes. The observation of the U20 imino proton resonance (Fig. 2B Bottom) results from slower hydrogen exchange of this imino proton in the VEGF 164 -aptamer complex compared with the HBD-aptamer complex. This difference in hydrogen exchange kinetics, combined with the observed difference in aptamer binding energies between the HBD and VEGF 164 , suggest that the receptor binding domain is either providing additional interactions with the aptamer or indirectly stabilizing new or existing interactions of the aptamer with the HBD.
The Ca 2ϩ requirement for the formation of the VEGF 165 -aptamer complex is specific to this aptamer family and is not observed in other high-affinity aptamers to VEGF 165 (8, (23) (24) (25) . The results here show that Ca 2ϩ is also required for the HBD-aptamer complex formation. However, no Ca 2ϩ dependence was observed in the NMR spectra of the free aptamer or free HBD (data not shown), and the same small change in melting temperature of the aptamer (3°C) was observed upon addition of either Ca 2ϩ or Mg 2ϩ (8) Thus it appears the Ca 2ϩ binding site is formed only in the aptamer-protein complex, and this Ca 2ϩ binding site may contribute to the isoform-specific recognition of the aptamer. 31 P chemical shifts are sensitive to the local environment of phosphates in nucleic acids (21) . The HMG box protein SRY bound to its DNA promoter sequence is one of the few proteinnucleic acid systems that have been characterized by 31 P NMR (22) . This complex shows a 31 P chemical shift dispersion of 2.8 ppm with a number of resonances shifted away from standard DNA duplex 31 P chemical shifts. These nonstandard 31 P chemical shifts can arise from a variety of factors, including salt bridges between Arg or Lys residues and the phosphate groups, intermolecular or intramolecular hydrogen bonding, or metal coordination (21, 22, 26) . A large percentage (10 of 28) of the 31 P resonances in the HBD-aptamer complex have nonstandard chemical shifts (Fig. 2C Middle) consistent with the presence of multiple side-chain-aptamer or metal-aptamer interactions. Furthermore, except for the differences in linewidth, the 31 P fingerprint of the VEGF 164 -aptamer complex (Fig. 2C Bottom) is essentially unchanged from the HBD-aptamer complex. These data provide strong evidence that the aptamer engages in similar specific intermolecular interactions in both the HBD-and full-length VEGF 164 complexes.
The conformation of the HBD in the complex was also monitored by analysis of the diagnostic 1 H͞ 15 N chemical shifts of S121, T142, and T157 produced upon aptamer binding (Figs. 3 and 4) . Fig. 5A shows that this NMR signature is indeed observed in the spectrum of the VEGF 164 -aptamer complex. These data are consistent with the HBD adopting a similar structure in the HBDaptamer and VEGF 164 -aptamer complexes.
Recognition of the HBD in the VEGF165-Aptamer Complex. The binding and NMR data show that the HBD-aptamer complex represents an excellent model system for understanding the interactions in the larger VEGF 165 -aptamer complex. The 1 H͞ 15 N chemical shift changes induced by aptamer binding can be used to map the recognition surface on the HBD. Fig. 4B maps the chemical shifts changes on the secondary structure of the free HBD (6) . The residues with large chemical shift changes (including the NMR fingerprint S121, T142, and T157) are located in the two central loops (regions I and III in Fig. 4A ) and before the ␣ helix (region II). S121 in region I displays the largest chemical shift change upon aptamer binding. The mechanism for formation of a photo-crosslink between 5-iodo-U14 and C137 requires stacking of the base and the disulfide bond (8, 27) . Thus the photo-crosslink to C137, which forms a disulfide bond with C120, is consistent with the aptamer being close to S121. The observed chemical shift changes suggest that the aptamer interacts with the two central loops in the HBD (regions I and III in Fig. 4A ). Therefore the chemical shift changes in region II could arise from either the large aptamer wrapping around the HBD to interact with region II or a local conformational change in the hinge region II that brings the two central loops together to form a contiguous binding site for the aptamer.
Most of the structurally characterized aptamers bind their ligands by an induced fit-type mechanism with the aptamer being well ordered in the complex but only partially structured in the free form (28, 29) . This type of induced fit requires an entropic cost for ordering the aptamer, which will reduce the overall binding affinity. Thus, higher affinity could be obtained by a mechanism where two rigid bodies form a complex with no additional ordering of the ligand or the aptamer. In our system, the HBD forms a relatively rigid secondary structure stabilized by four disulfide bonds. In addition, the secondary structure of the aptamer is thermodynamically stabilized by the 2Јfluoro modifications (8) , which greatly enhance helix formation because of their strong preference for the 3Јendo sugar pucker (30) . Therefore, this VEGF aptamer may be more structured in the free state than most other RNA-based aptamers. Because the stable secondary structure provides a preformed scaffold, only limited folding of the internal loop may be required for VEGF 164 binding.
Biological Implications for VEGF165 Inhibition by the Aptamer. The VEGF aptamer is a potent inhibitor of VEGF 165 -mediated angiogenesis and effectively blocks the interactions with the cell surface tyrosine kinase receptors VEGFR-1 and VEGFR-2 (8). All isoforms of VEGF, including VEGF 121 , which lacks the HBD, activate VEGFR-1 and VEGFR-2 (1). Thus, it might initially seem unlikely that an aptamer that interacts with the HBD would block receptor binding. However, the results here clearly show that the aptamer interacts predominantly with the HBD of full-length VEGF 165 . One possibility is that the aptamer inhibits VEGF 165 through a steric interference mechanism, where the bulky aptamer prevents interaction of the receptorbinding domain with the cell-surface receptors. Several natural antiangiogenic proteins have been previously identified that support this hypothesis. The metalloprotease ADAMTS1͞ METH1 (31), heparin affinity regulatory peptide HARP (32) , and connective tissue growth factor CTGF (33) have been shown to specifically target the VEGF 165 isoform by binding to the HBD (1) . Thus this nucleic acid aptamer appears to be mimicking a natural protein-associated interference mechanism for inhibiting the angiogenic activity of VEGF 165 .
Another possible role of the HBD is to increase the local concentration of VEGF 165 at the cell surface by interacting with heparan sulfate proteoglycans (1). Having VEGF 165 bound to the cell surface greatly enhances the probability of receptor binding by restricting diffusion of VEGF 165 to two dimensions. Thus the therapeutic activity of this aptamer may arise by capturing soluble VEGF 165 , therefore preventing interactions with heparan on cell surface proteoglycans. VEGF 165 -induced signaling through VEGFR-2 is further enhanced by the coreceptor neuropilin 1 (34, 35) . Association of VEGFR-2 and neuropilin 1 leads to tyrosine kinase activity of VEGFR-2 at Ϸ10-fold lower concentrations of VEGF 165 than of VEGF 121 (35) . Neuropilin 1 recognizes the HBD of VEGF 165 (34) . Thus an important function of the VEGF aptamer may be to block the interaction between neuropilin 1 and VEGF 165 , thereby suppressing VEGF 165 -induced pathology of the vasculature.
Conclusions
The VEGF aptamer inhibits angiogenesis by specifically recognizing the HBD of VEGF 165 . The data presented here demonstrate that the HBD is the primary target of the aptamer and that interactions with the HBD provide most of the binding energy in the VEGF 165 -aptamer complex. The aptamer not only binds to the HBD in vitro, but also effectively competes with VEGF 165 for aptamer binding in vivo. Comparison of NMR spectra of the HBD-and VEGF 164 -aptamer complexes demonstrates that the same molecular interactions are present in both complexes. Therefore, the HBD-aptamer complex is an important model system for understanding the molecular recognition in the full-length VEGF 165 -aptamer complex. We propose that both the HBD and VEGF 165 use the same mechanism of recognition for binding to the aptamer and that interactions with the HBD lead to the isoform-specific inhibition of VEGF 165 .
